Neovii is an independent, global biopharmaceutical company with a patient-focused mission to develop and bring to market novel life-transforming therapies to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders.
Products, services, technology
Grafalon®, has been used for over 30 years to treat patients. It has approval for use in immunosuppressive therapies for prevention of graft- versus- host disease in stem cell transplantation, prevention and treatment of rejection in solid organ transplantation and in treatment of aplastic anemia.
- https://neovii.com/
- +41 55 210 05 00
- info@neovii.com
